Friday, 16 October 2026European Markets

OTELLO CORPORATION Stock Bullish Momentum With A 19% Jump So Far On Tuesday

Loading stream...

(VIANEWS) - Shares of OTELLO CORPORATION (Oslo Børs Benchmark Index_GI: OTEC.OL) rose by a staggering 19.74% to kr9.10 at 11:37 EST on Tuesday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is sliding 0.18% to kr1,229.79, following the last session's downward trend. This seems, at the moment, a somewhat negative trend exchanging session today.

OTELLO CORPORATION's last close was kr7.60, 76.25% under its 52-week high of kr32.00.

About OTELLO CORPORATION

Otello Corporation ASA provides cloud-based network solutions for mobile operators. It offers RocketColony, which enables mobile operators to optimize their network performance and quality, as well as operates as a mobile media and entertainment company. The company was formerly known as Opera Software ASA and changed its name to Otello Corporation ASA in January 2018. The company was incorporated in 1995 and is based in Oslo, Norway.

Earnings Per Share

As for profitability, OTELLO CORPORATION has a trailing twelve months EPS of kr1.87.

PE Ratio

OTELLO CORPORATION has a trailing twelve months price to earnings ratio of 4.87. Meaning, the purchaser of the share is investing kr4.87 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.84%.

Volatility

OTELLO CORPORATION's last week, last month's, and last quarter's current intraday variation average was a positive 0.47%, a negative 0.03%, and a positive 2.31%.

OTELLO CORPORATION's highest amplitude of average volatility was 1.53% (last week), 1.79% (last month), and 2.31% (last quarter).

More news about OTELLO CORPORATION (OTEC.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com